In individual experiments, recombinant, plasma, and de-glycosylated were added to the bulk phase at a concentration of 2.5 µg/mL and absorbed to a TO/W interface. Peptide adsorption decreased γ from γ TO to an equilibrium value (γ eq ). This corresponded to an increase in surface pressure (П) of ΔП. Plasma and de-glycosylated apoC-III exhibited similar adsorption kinetics, and both increased П by 14 mN/m. peptides. Each data set was fit linearly, and these linear regressions were significant (-0.99 < R < -0.96, p < 0.0001). X-intercepts represent Π EX , the pressure at which a peptide cannot bind POPC/TO/W interfaces. Recombinant apoC-III modified these interfaces to a greater extent than native and deglycosylated plasma forms of apoC-III, as indicated by ΔП values that were 2 to 3 mN/m higher at all П i .
Recombinant apoC-III also showed the ability to insert into POPC/TO/W interfaces of higher pressures, as indicated by higher П EX than the glycosylated and de-glycosylated plasma forms of apoC-III.
Supplemental Fig. S3: The C-terminal 6-His tag in recombinant apoC-III increases its retention pressure at lipid/water interfaces of varying POPC concentrations.
In separate experiments, all three apoC-III variants were added to the bulk phase at 2. 5 µg/mL and adsorbed to a TO/W interface or POPC/TO/W interfaces of various initial pressures (П i ). After a 150-mL washout, each peptide/lipid/water interface was expanded and compressed at a rate of 1.2 µL/min, similar to the protocol shown in Fig. 4A . Π i values were converted to Γ POPC , as described previously (49) . γ values during the compression phase were converted to Π and the retention pressures ( ENV ) of apoC-III peptides at lipid surfaces were calculated as described at a TO/W interface in experiments. Linear regressions were applied to all plots. These fits were significant, with 0.95 < R < 0.99, p < 0.004 for plots in panels (B-D). R = 0.77, p = 0.12 for the linear regression in (A).
